AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ABIONYX Pharma

Share Issue/Capital Change Jan 7, 2026

1062_iss_2026-01-07_0a5d01e2-d163-4ed7-8047-25010a28b3f4.pdf

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Press release

Half-yearly report on the liquidity contract with TP ICAP (Europe) SA

Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on December 31, 2025:

• Number of shares: 63,024 • Cash balance: 250,951.67 €

During the 2 nd half of 2025, a total of :

PURCHASE 437,203 shares 1,389,323.53 € 369 transactions
SALE 536,477 shares 1,560,333.66 € 502 transactions

As a reminder, at the half-yearly balance sheet dated June 30, 2025, the following assets were included in the liquidity account:

• Number of shares: 162,298 shares

• Cash balance: 86,279.52 €

When the liquidity contract was set up, the following resources were made available:

• Number of shares: 131,000 shares

• Cash balance: 40,801.20 €

ANNEX H2 2025

Purchases Sales
ABNX FP Number of
transactions
Number of
shares
Capital in
EUR
Number of
transactions
Number
of shares
Capital in
EUR
Total 369 437 203 1 389 323,53 502 536 477 1 560 333,66
20250701 1 1 1,19 3 2 902 3 492,92
20250702 1 1 1,21 2 224 271,49
20250703 2 2 271 2 707,06 2 2 2,44
20250704 1 1 1,21 1 1 1,21
20250707 1 1 1,21 1 1 1,21
20250708 1 1 1,21 1 1 1,21
20250709 1 1 1,19 1 1 1,19
20250710 1 1 1,21 1 1 1,21
20250711 1 1 1,21 2 1 781 2 172,81
20250714 1 1 1,22 2 32 39,17
20250715 1 1 1,23 1 1 1,23
20250716 1 1 1,23 1 1 1,23
20250717 1 1 1,23 1 1 1,23
20250718 1 1 1,23 2 2 211 2 746,05
20250721 1 1 1,26 2 153 193,08
20250722 1 1 1,25 1 1 1,25
20250723 1 1 1,26 5 8 691 11 045,44
20250724 1 1 1,30 5 12 291 16 286,42
20250725 3 3 681 4 900,69 4 7 551 10 418,87
20250728 1 1 1,39 11 30 861 44 685,19
20250729 3 4 551 6 939,43 11 23 541 38 883,67
20250730 7 16 231 28 984,31 1 1 1,85
20250731 11 26 661 43 396,07 1 1 1,75
20250801 5 8 061 12 270,79 5 8 409 13 719,53
20250804 1 1 1,63 9 22 381 37 265,25
20250805 3 3 082 5 176,63 5 8 621 15 063,56
20250806 1 1 1,73 4 3 162 5 499,94
20250807 6 13 921 22 958,52 1 1 1,74
20250808 6 11 283 17 654,04 1 1 1,61
20250811 1 1 1,60 6 16 139 26 625,15
20250812 1 1 1,67 1 1 1,67
20250813 1 1 1,82 5 8 561 15 592,26
20250814 2 3 041 5 552,91 6 9 801 18 728,69
20250815 3 4 441 8 081,58 3 2 471 4 694,90
20250818 1 1 1,85 5 7 381 13 761,45
20250819 1 1 1,90 5 6 761 13 001,38
20250820 1 1 1,92 2 1 041 1 994,56
20250821 1 1 1,91 4 4 111 7 922,95
20250822 1 1 1,92 11 16 261 33 277,95
20250825 1 1 2,15 11 12 341 28 080,35
20250826 9 29 511 61 139,20 4 2 261 5 134,54
20250827 1 1 2,06 11 15 911 35 190,61
20250828 1 1 3,00 11 12 281 36 843,00
20250829 3 4 451 12 561,07 11 9 471 29 076,87
20250901 1 1 3,58 11 8 281 30 366,58
20250902 11 21 591 88 354,20 5 2 251 10 356,40
20250903 7 11 071 39 819,29 3 1 321 5 059,59
20250904 1 1 3,67 9 9 931 37 813,67
20250905 6 9 721 35 058,97 2 146 554,77
20250908 10 17 481 58 490,32 1 1 3,67
20250909 2 1 071 3 288,01 3 4 301 15 058,31
20250910 5 4 381 15 945,72 2 1 111 4 210,62
20250911 1 1 3,69 10 16 481 63 688,84
20250912 2 1 741 6 624,56 5 5 471 21 652,16
20250915 1 1 4,05 7 7 691 31 674,55
20250916 2 1 951 7 999,10 1 1 4,10
20250917 3 2 701 10 539,33 1 1 3,93
20250918 5 7 061 26 397,84 4 1 418 5 548,50
20250919 1 1 3,98 4 3 861 15 370,43
20250922 4 4 521 16 592,07 4 3 551 13 974,17
20250923 1 1 3,90 2 741 2 897,30
20250924 2 2 151 8 238,42 5 4 321 17 201,42
20250925 3 2 981 11 542,61 2 701 2 775,91
20250926 8 11 691 42 489,70 1 1 3,80
20250929 1 1 3,65 1 1 3,65
20250930 6 8 666 27 625,95 3 1 801 6 087,45
20251001 1 1 3,30 5 5 201 17 679,60
20251002 4 4 031 14 056,97 1 1 3,57
20251003 1 1 3,50 2 961 3 363,50
20251006 4 3 981 13 425,80 3 1 941 6 793,50
20251007 3 2 571 8 573,54 1 1 3,34
20251008 1 1 3,36 5 6 041 20 796,66
20251009 3 2 661 9 086,46 3 1 901 6 672,66
20251010 4 3 981 13 624,80 1 1 3,50
20251013 1 1 3,31 6 7 491 25 790,01
20251014 4 4 201 14 399,15 1 1 3,45
20251015 1 1 3,36 7 9 231 32 617,96
20251016 2 694 2 415,21 3 1 681 6 014,02
20251017 3 2 941 10 387,78 1 1 3,58
20251020 5 6 851 23 172,65 5 5 071 18 272,75
20251021 6 9 251 29 989,79 1 1 3,39
20251022 1 1 3,60 11 16 811 60 519,60
20251023 4 4 571 16 671,75 5 4 621 17 702,95
20251024 1 1 3,80 10 11 221 44 748,50
20251027 4 3 720 14 789,73 10 8 961 38 919,58
20251028 1 1 4,55 11 9 141 43 405,35
20251029 9 17 141 80 006,34 5 2 491 12 793,24
20251030 7 10 551 45 404,28 1 1 4,48
20251031 5 6 161 25 646,05 5 4 551 20 164,05
20251103 3 2 641 10 780,86 5 4 691 20 122,46
20251104 3 2 791 11 169,73 6 5 701 24 018,23
20251105 6 8 891 35 906,45 1 1 4,15
20251106 1 1 3,93 10 12 201 50 259,43
20251107 3 4 101 17 236,46 5 3 771 16 503,76
20251110 4 4 481 18 568,60 2 681 2 914,60
20251111 1 1 4,18 4 2 941 12 445,78
20251112 7 10 501 42 742,65 5 4 111 18 133,25
20251113 3 2 821 11 148,77 3 1 581 6 434,67
20251114 2 291 1 155,34 4 1 631 6 663,64
20251117 1 1 4,28 5 4 631 19 850,73
20251118 3 2 871 11 949,27 1 1 4,17
20251119 1 1 4,22 3 1 541 6 572,62
20251120 3 2 821 11 769,34 3 1 481 6 361,14
20251121 1 1 4,35 9 9 551 42 161,65
20251124 4 4 901 20 063,60 1 1 4,20
20251125 1 1 4,18 5 4 061 17 465,18
20251126 5 6 881 29 098,30 1 1 4,30
20251127 3 2 224 9 072,46 1 1 4,08
20251128 2 2 111 8 528,48 1 1 4,08
20251201 4 4 241 17 022,46 1 1 4,06
20251202 4 4 071 15 973,93 1 1 4,03
20251203 5 6 181 23 005,50 1 1 3,80
20251204 1 1 3,79 5 5 881 22 765,19
20251205 1 1 3,91 3 1 851 7 265,61
20251208 1 1 3,90 1 1 3,90
20251209 3 2 671 10 208,65 2 891 3 483,75
20251210 4 3 951 14 989,23 1 1 3,83
20251211 4 3 851 14 083,72 1 1 3,72
20251212 4 3 721 13 236,49 2 1 011 3 710,29
20251215 1 1 3,53 2 1 051 3 731,03
20251216 4 3 721 12 713,02 1 1 3,42
20251217 9 12 721 39 905,26 1 1 3,16
20251218 1 1 3,20 6 9 481 31 218,90
20251219 1 1 3,41 6 8 501 29 709,51
20251222 5 5 991 20 522,54 1 1 3,54
20251223 1 1 3,40 4 4 381 15 331,30
20251224 1 1 3,49 3 2 111 7 462,79
20251225 0 0 0,00 0 0 0,00
20251226 0 0 0,00 0 0 0,00
20251229 3 2 591 8 925,20 2 1 011 3 568,80
20251230 2 1 831 6 408,52 5 6 101 22 274,12
20251231 1 1 3,67 6 7 291 27 527,77

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through breakthrough biotherapies that address life-threatening conditions with no effective treatments. Leveraging its proprietary apoA-I–based technology platform, ABIONYX Pharma develops innovative biologics and HDL-derived vectors that target the immune and inflammatory dysregulation underlying sepsis and other severe diseases. With a strong scientific foundation and a growing network of global clinical partners, ABIONYX Pharma aims to redefine the standard of care in sepsis and to bring critical care solutions to patients worldwide.

Contacts :

ABIONYX Pharma [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.